BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras -Mutant Non-Small Cell Lung Cancer

mutation is present in approximately 30% of human lung adenocarcinomas. Although recent advances in targeted therapy have shown great promise, effective targeting of KRAS remains elusive, and concurrent alterations in tumor suppressors render mutant tumors even more resistant to existing therapies....

Full description

Saved in:
Bibliographic Details
Published inCancer immunology research Vol. 6; no. 10; p. 1234
Main Authors Adeegbe, Dennis O, Liu, Shengwu, Hattersley, Maureen M, Bowden, Michaela, Zhou, Chensheng W, Li, Shuai, Vlahos, Raven, Grondine, Michael, Dolgalev, Igor, Ivanova, Elena V, Quinn, Max M, Gao, Peng, Hammerman, Peter S, Bradner, James E, Diehl, J Alan, Rustgi, Anil K, Bass, Adam J, Tsirigos, Aristotelis, Freeman, Gordon J, Chen, Huawei, Wong, Kwok-Kin
Format Journal Article
LanguageEnglish
Published United States 01.10.2018
Online AccessGet more information

Cover

Loading…
Abstract mutation is present in approximately 30% of human lung adenocarcinomas. Although recent advances in targeted therapy have shown great promise, effective targeting of KRAS remains elusive, and concurrent alterations in tumor suppressors render mutant tumors even more resistant to existing therapies. Contributing to the refractoriness of -mutant tumors are immunosuppressive mechanisms, such as increased presence of suppressive regulatory T cells (Treg) in tumors and elevated expression of the inhibitory receptor PD-1 on tumor-infiltrating T cells. Treatment with BET bromodomain inhibitors is beneficial for hematologic malignancies, and they have Treg-disruptive effects in a non-small cell lung cancer (NSCLC) model. Targeting PD-1-inhibitory signals through PD-1 antibody blockade also has substantial therapeutic impact in lung cancer, although these outcomes are limited to a minority of patients. We hypothesized that the BET bromodomain inhibitor JQ1 would synergize with PD-1 blockade to promote a robust antitumor response in lung cancer. In the present study, using ; (KP) mouse models of NSCLC, we identified cooperative effects between JQ1 and PD-1 antibody. The numbers of tumor-infiltrating Tregs were reduced and activation of tumor-infiltrating T cells, which had a T-helper type 1 (Th1) cytokine profile, was enhanced, underlying their improved effector function. Furthermore, lung tumor-bearing mice treated with this combination showed robust and long-lasting antitumor responses compared with either agent alone, culminating in substantial improvement in the overall survival of treated mice. Thus, combining BET bromodomain inhibition with immune checkpoint blockade offers a promising therapeutic approach for solid malignancies such as lung adenocarcinoma. .
AbstractList mutation is present in approximately 30% of human lung adenocarcinomas. Although recent advances in targeted therapy have shown great promise, effective targeting of KRAS remains elusive, and concurrent alterations in tumor suppressors render mutant tumors even more resistant to existing therapies. Contributing to the refractoriness of -mutant tumors are immunosuppressive mechanisms, such as increased presence of suppressive regulatory T cells (Treg) in tumors and elevated expression of the inhibitory receptor PD-1 on tumor-infiltrating T cells. Treatment with BET bromodomain inhibitors is beneficial for hematologic malignancies, and they have Treg-disruptive effects in a non-small cell lung cancer (NSCLC) model. Targeting PD-1-inhibitory signals through PD-1 antibody blockade also has substantial therapeutic impact in lung cancer, although these outcomes are limited to a minority of patients. We hypothesized that the BET bromodomain inhibitor JQ1 would synergize with PD-1 blockade to promote a robust antitumor response in lung cancer. In the present study, using ; (KP) mouse models of NSCLC, we identified cooperative effects between JQ1 and PD-1 antibody. The numbers of tumor-infiltrating Tregs were reduced and activation of tumor-infiltrating T cells, which had a T-helper type 1 (Th1) cytokine profile, was enhanced, underlying their improved effector function. Furthermore, lung tumor-bearing mice treated with this combination showed robust and long-lasting antitumor responses compared with either agent alone, culminating in substantial improvement in the overall survival of treated mice. Thus, combining BET bromodomain inhibition with immune checkpoint blockade offers a promising therapeutic approach for solid malignancies such as lung adenocarcinoma. .
Author Quinn, Max M
Dolgalev, Igor
Wong, Kwok-Kin
Zhou, Chensheng W
Ivanova, Elena V
Grondine, Michael
Gao, Peng
Bass, Adam J
Li, Shuai
Rustgi, Anil K
Freeman, Gordon J
Hattersley, Maureen M
Hammerman, Peter S
Tsirigos, Aristotelis
Chen, Huawei
Liu, Shengwu
Bradner, James E
Diehl, J Alan
Bowden, Michaela
Adeegbe, Dennis O
Vlahos, Raven
Author_xml – sequence: 1
  givenname: Dennis O
  surname: Adeegbe
  fullname: Adeegbe, Dennis O
  email: Kwok-Kin.Wong@nyumc.org, Dennis.Adeegbe@nyumc.org
  organization: Laura & Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, New York. Kwok-Kin.Wong@nyumc.org Dennis.Adeegbe@nyumc.org
– sequence: 2
  givenname: Shengwu
  surname: Liu
  fullname: Liu, Shengwu
  organization: Broad Institute of Harvard and MIT, Cambridge, Massachusetts
– sequence: 3
  givenname: Maureen M
  surname: Hattersley
  fullname: Hattersley, Maureen M
  organization: Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts
– sequence: 4
  givenname: Michaela
  surname: Bowden
  fullname: Bowden, Michaela
  organization: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
– sequence: 5
  givenname: Chensheng W
  surname: Zhou
  fullname: Zhou, Chensheng W
  organization: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
– sequence: 6
  givenname: Shuai
  surname: Li
  fullname: Li, Shuai
  organization: Department of Pathology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China
– sequence: 7
  givenname: Raven
  surname: Vlahos
  fullname: Vlahos, Raven
  organization: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
– sequence: 8
  givenname: Michael
  surname: Grondine
  fullname: Grondine, Michael
  organization: Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts
– sequence: 9
  givenname: Igor
  surname: Dolgalev
  fullname: Dolgalev, Igor
  organization: Applied Bioinformatics Laboratories and Department of Pathology, New York University School of Medicine, New York, New York
– sequence: 10
  givenname: Elena V
  surname: Ivanova
  fullname: Ivanova, Elena V
  organization: Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts
– sequence: 11
  givenname: Max M
  surname: Quinn
  fullname: Quinn, Max M
  organization: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
– sequence: 12
  givenname: Peng
  surname: Gao
  fullname: Gao, Peng
  organization: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
– sequence: 13
  givenname: Peter S
  surname: Hammerman
  fullname: Hammerman, Peter S
  organization: Novartis Institutes for Biomedical Research, Cambridge, Massachusetts
– sequence: 14
  givenname: James E
  surname: Bradner
  fullname: Bradner, James E
  organization: Novartis Institutes for Biomedical Research, Cambridge, Massachusetts
– sequence: 15
  givenname: J Alan
  surname: Diehl
  fullname: Diehl, J Alan
  organization: Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina
– sequence: 16
  givenname: Anil K
  surname: Rustgi
  fullname: Rustgi, Anil K
  organization: Division of Gastroenterology, Departments of Medicine and Genetics, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
– sequence: 17
  givenname: Adam J
  surname: Bass
  fullname: Bass, Adam J
  organization: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
– sequence: 18
  givenname: Aristotelis
  orcidid: 0000-0002-7512-8477
  surname: Tsirigos
  fullname: Tsirigos, Aristotelis
  organization: Applied Bioinformatics Laboratories and Department of Pathology, New York University School of Medicine, New York, New York
– sequence: 19
  givenname: Gordon J
  surname: Freeman
  fullname: Freeman, Gordon J
  organization: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
– sequence: 20
  givenname: Huawei
  orcidid: 0000-0002-6037-3808
  surname: Chen
  fullname: Chen, Huawei
  organization: Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts
– sequence: 21
  givenname: Kwok-Kin
  surname: Wong
  fullname: Wong, Kwok-Kin
  email: Kwok-Kin.Wong@nyumc.org, Dennis.Adeegbe@nyumc.org
  organization: Laura & Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, New York. Kwok-Kin.Wong@nyumc.org Dennis.Adeegbe@nyumc.org
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30087114$$D View this record in MEDLINE/PubMed
BookMark eNo1UM1OwzAYixCIjbFHAOUFMvLXtDtuZYOJ8aMxztPXJGWBNpnaVIg7D04lhg-2ZVk--AKd-uAtQleMThhLshsuuCKKKjXJVxvCMkJpmp6g4TFP5QCN2_aD9sgyyRJ5jgai9yljcoh-5ostnjehDibU4Dxe-b0rXHTB4zyEg20g2hZ_ubjHL7eE4XkV9CcYi2PAS9CucrFv4JmPLnZ1aPDGtofgW4v7sYcGWkweuwg-4qfgyWsNVYVz29O68-84B69tc4nOSqhaOz7qCL0tF9v8nqyf71b5bE20VCISkSRlIcVUMp6WRpmiyDgAMCiyqQElQXJjSk7TEoTKmKU6FdrohFIuSqMVH6Hrv91DV9TW7A6Nq6H53v3fwX8B3mhkYg
CitedBy_id crossref_primary_10_1016_j_trecan_2023_07_015
crossref_primary_10_1021_acs_nanolett_9b00021
crossref_primary_10_3389_fimmu_2021_669992
crossref_primary_10_1136_jitc_2022_004605
crossref_primary_10_1016_j_apsb_2021_11_020
crossref_primary_10_1016_j_it_2021_03_006
crossref_primary_10_1038_s41467_024_46778_8
crossref_primary_10_1016_j_tem_2022_04_002
crossref_primary_10_1158_1535_7163_MCT_18_1206
crossref_primary_10_1016_j_bioactmat_2024_05_042
crossref_primary_10_1136_jitc_2023_006782
crossref_primary_10_1007_s00535_022_01915_2
crossref_primary_10_3389_fimmu_2021_731947
crossref_primary_10_3389_fphar_2020_582955
crossref_primary_10_1016_j_crmeth_2021_100080
crossref_primary_10_1111_imm_13058
crossref_primary_10_3389_fimmu_2020_629722
crossref_primary_10_3390_cells11182783
crossref_primary_10_1101_cshperspect_a038000
crossref_primary_10_3390_cells12030365
crossref_primary_10_1016_j_ccell_2023_09_006
crossref_primary_10_1038_s41571_019_0266_5
crossref_primary_10_1111_cas_14588
crossref_primary_10_2139_ssrn_3969261
crossref_primary_10_1016_j_semcancer_2020_11_006
crossref_primary_10_3390_cancers12040784
crossref_primary_10_1002_cac2_12313
crossref_primary_10_1038_s41392_023_01480_x
crossref_primary_10_3389_fonc_2019_01556
crossref_primary_10_1093_neuonc_noaa084
crossref_primary_10_1158_1535_7163_MCT_23_0303
crossref_primary_10_1016_j_apsb_2021_09_022
crossref_primary_10_1038_s41419_022_05505_1
crossref_primary_10_1016_j_ymthe_2022_07_022
crossref_primary_10_1186_s12929_022_00893_0
crossref_primary_10_1016_j_canlet_2019_08_013
crossref_primary_10_1038_s41417_024_00778_4
crossref_primary_10_3390_v13061026
crossref_primary_10_1158_1078_0432_CCR_23_3504
crossref_primary_10_4049_immunohorizons_1900037
crossref_primary_10_3389_fimmu_2019_00454
crossref_primary_10_3389_fimmu_2022_894508
crossref_primary_10_1016_j_drudis_2022_103435
crossref_primary_10_1080_14728222_2020_1723548
crossref_primary_10_1186_s40164_022_00356_0
crossref_primary_10_3389_fimmu_2018_03104
crossref_primary_10_3390_epigenomes4040027
crossref_primary_10_1016_j_cej_2024_149446
crossref_primary_10_3390_cancers14112761
crossref_primary_10_1158_0008_5472_CAN_19_3674
crossref_primary_10_3390_cancers13143595
crossref_primary_10_3390_biom10071061
crossref_primary_10_1002_cam4_2895
crossref_primary_10_1016_j_trecan_2019_02_003
crossref_primary_10_1016_j_trecan_2020_02_003
crossref_primary_10_1080_13102818_2019_1669489
crossref_primary_10_1158_2326_6066_CIR_21_0224
crossref_primary_10_1002_jcb_29420
crossref_primary_10_3389_fonc_2021_760789
crossref_primary_10_1073_pnas_2116764119
crossref_primary_10_1186_s13073_021_00888_w
crossref_primary_10_1016_j_stem_2021_04_011
crossref_primary_10_1002_cam4_2492
crossref_primary_10_1038_s41573_020_0077_5
crossref_primary_10_1002_jmri_28010
crossref_primary_10_1016_j_jid_2018_12_024
crossref_primary_10_1038_s41419_022_05123_x
crossref_primary_10_1016_j_drudis_2020_07_006
crossref_primary_10_1093_lifemedi_lnad019
crossref_primary_10_1002_ctm2_718
crossref_primary_10_3390_cancers11030304
ContentType Journal Article
Copyright 2018 American Association for Cancer Research.
Copyright_xml – notice: 2018 American Association for Cancer Research.
DBID NPM
DOI 10.1158/2326-6066.CIR-18-0077
DatabaseName PubMed
DatabaseTitle PubMed
DatabaseTitleList PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 2326-6074
ExternalDocumentID 30087114
Genre Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: U01 CA213333
– fundername: NCI NIH HHS
  grantid: P01 CA098101
– fundername: NCI NIH HHS
  grantid: R01 CA219670
– fundername: NCI NIH HHS
  grantid: P01 CA154303
– fundername: NCI NIH HHS
  grantid: R01 CA166480
– fundername: NCI NIH HHS
  grantid: R01 CA216188
– fundername: NCI NIH HHS
  grantid: R01 CA205150
– fundername: NCI NIH HHS
  grantid: R01 CA140594
GroupedDBID 53G
AAJMC
ADCOW
AENEX
AFHIN
ALMA_UNASSIGNED_HOLDINGS
EBS
EJD
H13
NPM
OK1
RCR
RHI
ID FETCH-LOGICAL-c463t-355fb4394127fd6dbb82aaa1ab89da64a42ddf207fa3681e0c73cdc50023fdc62
IngestDate Wed Oct 16 00:51:33 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Language English
License 2018 American Association for Cancer Research.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c463t-355fb4394127fd6dbb82aaa1ab89da64a42ddf207fa3681e0c73cdc50023fdc62
ORCID 0000-0002-7512-8477
0000-0002-6037-3808
OpenAccessLink https://cancerimmunolres.aacrjournals.org/content/canimm/6/10/1234.full.pdf
PMID 30087114
ParticipantIDs pubmed_primary_30087114
PublicationCentury 2000
PublicationDate 2018-10-01
PublicationDateYYYYMMDD 2018-10-01
PublicationDate_xml – month: 10
  year: 2018
  text: 2018-10-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Cancer immunology research
PublicationTitleAlternate Cancer Immunol Res
PublicationYear 2018
SSID ssj0000884154
Score 2.485498
Snippet mutation is present in approximately 30% of human lung adenocarcinomas. Although recent advances in targeted therapy have shown great promise, effective...
SourceID pubmed
SourceType Index Database
StartPage 1234
Title BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras -Mutant Non-Small Cell Lung Cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/30087114
Volume 6
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBabFkIupe82faBDb0apH7KsPWa3Celjt6XdQG5BkuVkKbaXzZpAzv1X_XOdseUHYUsfF2MkIxvP59HMeOYbQt4EfgrbZsiRt1UxDkYpG2ujmK8ysOWSOBQK_-jO5uLklH84i89Go5-DrKVqow_Mzda6kv-RKoyBXLFK9h8k2y0KA3AO8oUjSBiOfyXjydEChFPm4Frm4OHDx3651HUOFnzn5Qr5kq0rX_vyjgXeBHau7yqtu2UcK9MQdCMxCeYL5OUag_mYMVsTiXxcqyuPzSpsM-zNy4J9y_E39hSDfZ8qzBZAwKyH1m0z4i2x5qThdnJcQl3M-TC19kLbRtMVxfLK-9ylBC2rOhR7aYuL66rXjDX_p4usz1SFeUJ9CHdSXjvF6fL_1TCMEcguIQ52oVrdgWknmPCbnj2tbhZDCPoDRQsbLt--A8RY1eAWE-Jg-v4rg7shbdHwehDkKq9hESErXxDwP8_eIuZup3bITiKxa8jcBYpqI0BKMI24qxmDh3q79ZH2yG67zC2_prZvFvfJPeeY0MMGZQ_IyBYPye7MpV48Ij8AbHQANtqDjfZgowg2imCjLdjopqQ92GgHNtqCjcJiCDbqwEY7sFEEG0Ww0QZaj8np8dFiesJcCw9muIg2DKzZTGPxdRAmGfYu0zJUSgVKy3GqBFc8TNMs9JNMRUIG1jdJZFIToymZpUaET8idoizsM0LHfiSt0FZGWcy1zaRWJkqVAYeEJ8LI5-Rp8_7OVw1Py3n7Zvd_O_OC7PVYfEnuZqAY7CuwMjf6dS3PX2U2e30
link.rule.ids 780
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=BET+Bromodomain+Inhibition+Cooperates+with+PD-1+Blockade+to+Facilitate+Antitumor+Response+in+Kras+-Mutant+Non-Small+Cell+Lung+Cancer&rft.jtitle=Cancer+immunology+research&rft.au=Adeegbe%2C+Dennis+O&rft.au=Liu%2C+Shengwu&rft.au=Hattersley%2C+Maureen+M&rft.au=Bowden%2C+Michaela&rft.date=2018-10-01&rft.eissn=2326-6074&rft.volume=6&rft.issue=10&rft.spage=1234&rft_id=info:doi/10.1158%2F2326-6066.CIR-18-0077&rft_id=info%3Apmid%2F30087114&rft_id=info%3Apmid%2F30087114&rft.externalDocID=30087114